Janus Henderson Group PLC reduced its stake in ABIVAX Société Anonyme (NASDAQ:ABVX - Free Report) by 65.1% in the 3rd quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The institutional investor owned 410,710 shares of the company's stock after selling 764,804 shares during the quarter. Janus Henderson Group PLC owned approximately 0.65% of ABIVAX Société Anonyme worth $4,740,000 at the end of the most recent quarter.
Several other large investors also recently added to or reduced their stakes in the stock. abrdn plc raised its holdings in ABIVAX Société Anonyme by 167.7% in the 3rd quarter. abrdn plc now owns 316,431 shares of the company's stock valued at $3,645,000 after buying an additional 198,225 shares during the period. Walleye Capital LLC raised its stake in shares of ABIVAX Société Anonyme by 45.8% in the 3rd quarter. Walleye Capital LLC now owns 257,417 shares of the company's stock valued at $2,965,000 after acquiring an additional 80,807 shares during the period. Finally, BNP Paribas Financial Markets lifted its holdings in shares of ABIVAX Société Anonyme by 82.6% in the 3rd quarter. BNP Paribas Financial Markets now owns 13,044 shares of the company's stock worth $150,000 after acquiring an additional 5,900 shares during the last quarter. 47.91% of the stock is currently owned by hedge funds and other institutional investors.
ABIVAX Société Anonyme Price Performance
Shares of ABVX traded down $0.64 during midday trading on Wednesday, reaching $7.94. The stock had a trading volume of 406,013 shares, compared to its average volume of 94,341. The company's fifty day simple moving average is $9.57 and its two-hundred day simple moving average is $11.41. ABIVAX Société Anonyme has a 1-year low of $7.81 and a 1-year high of $17.02.
Analyst Ratings Changes
A number of analysts have issued reports on the company. JMP Securities initiated coverage on ABIVAX Société Anonyme in a research report on Wednesday, December 4th. They issued an "outperform" rating and a $33.00 target price on the stock. Citizens Jmp upgraded ABIVAX Société Anonyme to a "strong-buy" rating in a report on Wednesday, December 4th. One analyst has rated the stock with a hold rating, five have issued a buy rating and one has issued a strong buy rating to the company's stock. Based on data from MarketBeat, the company currently has a consensus rating of "Buy" and an average target price of $38.67.
View Our Latest Research Report on ABVX
ABIVAX Société Anonyme Profile
(
Free Report)
ABIVAX Société Anonyme, a clinical-stage biotechnology company, focuses on developing therapeutics that harness the body's natural regulatory mechanisms to stablize the immune response in patients with chronic inflammatory diseases. The company is evaluating its lead drug candidate, obefazimod, in Phase 3 clinical trials for the treatment of moderately to severely active ulcerative colitis in adults.
Read More
Before you consider ABIVAX Société Anonyme, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and ABIVAX Société Anonyme wasn't on the list.
While ABIVAX Société Anonyme currently has a "Buy" rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Just getting into the stock market? These 10 simple stocks can help beginning investors build long-term wealth without knowing options, technicals, or other advanced strategies.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
